19 June 2018 | News
Kallyope will receive an upfront payment and research support for activities conducted in the collaboration.
Image credit- blog.efpsa.org
Kallyope Inc. and Novo Nordisk A/S have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes.
Kallyope has developed an innovative platform to interrogate the gut-brain axis and discover new medicines in multiple therapeutic areas. The platform integrates single-cell sequencing, bioinformatics, functional and anatomical circuit mapping, and organoids. It has enabled the discovery of new biological mechanisms, including multiple potential secreted products from the gut-brain axis that may play a role in metabolism.
Under a joint research plan, Kallyope and Novo Nordisk will collaborate on in vitro and in vivo studies to validate a number of product candidates. Following validation and option exercise, Novo Nordisk will assume responsibility for further preclinical and clinical development, manufacturing, and commercialization.